View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 11, 2016updated 13 Jul 2022 10:13am

BeiGene receives CFDA approval to conduct clinical trial of BGB-A317 to treat advanced solid tumours

Clinical-stage biopharmaceutical firm BeiGene has secured the Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to undertake clinical trials of BGB-A317 in China to treat advanced solid tumours.

Clinical-stage biopharmaceutical firm BeiGene has secured the Clinical Trial Application (CTA) approval from the China Food and Drug Administration (CFDA) to undertake clinical trials of BGB-A317 in China to treat advanced solid tumours.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

BGB-A317 is an investigational humanised monoclonal antibody belonging to a class of immuno-oncology agents known as immune checkpoint inhibitors.

It fuses with PD-1, a cell surface receptor responsible for downregulating the immune system by preventing the activation of T-cells.

BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of various cancers.

"This event marks the receipt of regulatory clearance for all four of our clinical-stage molecules for initiation of clinical trials in China."

BeiGene founder, CEO and chairman John Oyler said: “This event marks the receipt of regulatory clearance for all four of our clinical-stage molecules for initiation of clinical trials in China.

“The Chinese pharmaceutical market continues to grow robustly and is an important market for us.

“We are delighted to receive this clearance and look forward to commencing the development of BGB-A317 in China and updating the clinical data from the ongoing global study of BGB-A317.”

According to BeiGene head of regulatory affairs Wendy Yan, positive results from the Phase I dose-escalation trial in patients with advanced solid tumours conducted outside China have paved the way in securing the CTA approval.

Aside from China, BGB-A317 was approved to conduct clinical trials in Australia, New Zealand, the US and Taiwan.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena